论文部分内容阅读
目的探讨血管活性肠肽(VIP)对裸鼠MKN45移植瘤的影响。方法将18只人胃癌MKN45细胞株的移植瘤裸鼠随机均分为三组,分别每天皮下注射VIP 10μg·100μl-1.只-1(VIP组)、VIP受体拮抗剂[D-p-C1-phe6,Leu17]-VIP(V4380)10μg·100μl-1.只-1(拮抗剂组)和PBS100μl/只(对照组)。每周称量裸鼠体重及移植瘤体积,4周后处死裸鼠,称量移植瘤重量及体积。用免疫组化及RT-PCR检测移植瘤组织中胞外信号调节激酶(ERK)蛋白及mRNA表达的变化。结果给药第28天,VIP组裸鼠体重明显轻于拮抗剂组(P<0.05)。给药的第14、21天,VIP组移植瘤体积明显小于其它两组(P<0.01)。VIP组ERK蛋白的表达显著低于拮抗剂组(P<0.05)。结论 VIP可能通过抑制肿瘤细胞ERK/NF-κB通路对人胃癌细胞MKN45裸鼠移植瘤有潜在抑制作用。
Objective To investigate the effect of vasoactive intestinal peptide (VIP) on the transplanted tumor of MKN45 in nude mice. Methods Nude mice bearing 18 human gastric cancer cell line MKN45 were randomly divided into three groups: VIP 10 μg · 100 μl-1 · -1 (VIP group), VIP receptor antagonist [Dp-C1- phe6, Leu17] -VIP (V4380) 10 μg · 100 μl -1 only -1 (antagonist group) and PBS100 μl / control (control group). The weight of the nude mice and the volume of the xenografts were weighed every week. After 4 weeks, the nude mice were sacrificed and the weight and volume of the xenografts were weighed. The expression of extracellular signal-regulated kinase (ERK) in tumor tissue was detected by immunohistochemistry and RT-PCR. Results On the 28th day, the body weight of VIP group was significantly lower than that of the antagonist group (P <0.05). On the 14th and 21st day of administration, the volume of tumor in VIP group was significantly smaller than that in the other two groups (P <0.01). The expression of ERK protein in VIP group was significantly lower than that in antagonist group (P <0.05). Conclusion VIP may inhibit the transplanted human gastric cancer cell line MKN45 by inhibiting the ERK / NF-κB pathway of tumor cells.